Compounds > rimantadine hydrochloride
Page last updated: 2024-12-05

rimantadine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Rimantadine hydrochloride is an antiviral medication used to treat and prevent influenza A. It works by blocking the virus from entering cells, thus inhibiting viral replication. It is typically used for the treatment of influenza A in adults and children over 1 year of age, and is also used to prevent influenza A in individuals with weakened immune systems. The synthesis of rimantadine involves a multi-step process starting with the reaction of adamantane with nitrous acid, followed by a series of chemical transformations. Due to its effectiveness against influenza A, rimantadine is of significant importance in public health, particularly during flu outbreaks. Research continues to explore its potential applications, including its use against other viral infections, such as dengue fever and HIV. The mechanism of action and efficacy of rimantadine are also being investigated, as well as its possible side effects and interactions with other medications. '

Cross-References

ID SourceID
PubMed CID15165
CHEMBL ID535396
CHEMBL ID1200355
CHEBI ID8865
SCHEMBL ID40906
MeSH IDM0351818

Synonyms (119)

Synonym
rimantadine hydrochloride [usan:usp]
unii-jei07oos8y
jei07oos8y ,
rimantadine hcl
1-adamantanemethylamine, alpha-methyl-, hydrochloride
rimantadine hydrochloride [usan]
tricyclo(3.3.1.1(sup 3,7))-decane-1-methanamine, alpha-methyl-, hydrochloride
alpha-methyltricyclo(3.3.1.1(sup 3,7))decane-1-methanamine hydrochloride
alpha-methyl-1-adamantanemethylamine hydrochloride
tricyclo(3.3.1.13,7)decane-1-methanamine, alpha-methyl-, hydrochloride
nsc 206764
adamantane, 1-(1-aminoethyl)-, hydrochloride
oclovir
MLS000069661 ,
1-(1-adamantyl)ethylamine hydrochloride
algirem
exp-126
roflual
smr000059215
rimantadine hydrochloride ,
1501-84-4
C08094
flumadine
NCGC00159491-02
remantadine hydrochloride
nsc206764
.alpha.-methyl-1-adamantanemethylamine hydrochloride
exp 126
nsc-206764
meradane
meradan
jp 61
remantadine
1-(1-aminoethyl)adamantane hydrochloride
1-adamantanemethylamine, hydrochloride
D00901
rimantadine hydrochloride (usp)
flumadine (tn)
1-(1-adamantyl)ethylamine hydrochloride, 99%
smr000436311
MLS000332981
SR-01000631468-1
VU0244476-5
1-(1-adamantyl)ethanamine hydrochloride
CHEMBL535396
chebi:8865 ,
CHEMBL1200355
R0070
AKOS005267193
hydrochloride, rimantadine
[1-(1-adamantyl)ethyl]amine hydrochloride
tox21_111712
dtxsid1047813 ,
cas-1501-84-4
dtxcid3027790
1-(adamantan-1-yl)ethan-1-amine hydrochloride
EN300-08051
nsc759149
pharmakon1600-01505460
nsc-759149
MLS002548886
c12h22cln
1-adamantan-1-yl-ethylamine hydrochloride
AKOS016034989 ,
CCG-41384
FT-0603562
S5484
AKOS016340560
rimantadine hydrochloride [orange book]
rimantadine hydrochloride [who-dd]
rimantadine hydrochloride [mart.]
rimantadine hydrochloride [mi]
tricyclo(3.3.1.1(sup 3,7))-decane-1-methanamine, .alpha.-methyl-, hydrochloride
rimantadine hydrochloride [usp monograph]
rimantadine hydrochloride [usp-rs]
rimantadine hydrochloride [vandf]
CCG-220606
HY-B0338A
rimantadine (hydrochloride)
NC00674
SCHEMBL40906
NCGC00159491-04
tox21_111712_1
KS-5232
OZBDFBJXRJWNAV-UHFFFAOYSA-N
1-(adamantan-1-yl)ethanamine hydrochloride
rimantadinehydrochloride
Q-201673
molport-000-768-308
tricyclo[3.3.1.13,7]decane-1-methanamine, alpha-methyl-, hydrochloride (1:1), (alphas)-
mfcd00072023
1-(1-adamantyl)ethanamine;hydrochloride
sr-01000631468
SR-01000631468-4
AC-8480
rimantadine hydrochloride, united states pharmacopeia (usp) reference standard
rimantadine-d4 hcl (ethyl-d4)
J-006455
rimantadine, hcl
[1-(1-adamantyl)ethyl]amine hcl
alpha-methyl-1-adamantane-methanamine hydrochloride
alpha-methyl-tricyclo[3.3.1.13,7]decane-1-methanamine hydrochloride (1:1)
1-(tricyclo[3.3.1.13,7]dec-1-yl)ethanamine hydrochloride
j05ac02
diisopropylsulfide
SY057460
Q27108162
1-(1-aminoethyl)adamantane hcl
AS-12095
tricyclo[3.3.1.13,7]decane-1-methanamine, alpha-methyl-, hydrochloride (1:1)
rimantadine hcl pound>>hydrochloride, rimantadine;flumadine
BCP26342
tricyclo[3.3.1.13,7]decane-1-methanamine, -methyl-, hydrochloride (1:1), (s)-
BR164342
Z56872184
rimantadine hydrochloride (usan:usp)
rimantadine hydrochloride (usp monograph)
rimantadine hydrochloride (mart.)
rimantadine hydrochloride (usp-rs)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Microtubule-associated protein tauHomo sapiens (human)Potency39.81070.180013.557439.8107AID1468
AR proteinHomo sapiens (human)Potency10.68220.000221.22318,912.5098AID743035
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency0.79430.794321.275750.1187AID624246
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency35.48130.009610.525035.4813AID1479145
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency28.18383.981146.7448112.2020AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (67)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1426032Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 48 hrs by hemagglutination test2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID292962Antiviral activity against influenza A virus (H3N2)-induced cytopathogenicity in MDCK cells by MTS method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Influence of an additional 2-amino substituent of the 1-aminoethyl pharmacophore group on the potency of rimantadine against influenza virus A.
AID315461Antitrypanosomal activity against Trypanosoma brucei 427 at pH 7.42008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Design, synthesis, and trypanocidal activity of new aminoadamantane derivatives.
AID1156046Cytotoxicity against MDCK cells assessed as alteration in cell morphology after 72 hrs2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1426033Selectivity index, ratio of CTD50 for MDCK cells to ED50 for Influenza A virus (A/Puerto Rico/8/34(H1N1))2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID1426029Cytotoxicity against MDCK cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID1156041Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) harboring M2 S31N/V27T double mutant channel infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID292963Cytotoxicity against MDCK cells2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Influence of an additional 2-amino substituent of the 1-aminoethyl pharmacophore group on the potency of rimantadine against influenza virus A.
AID1124988Selectivity index, ratio of CTD50 for MDCK cells to ED50 for Influenza A virus (A/California/07/09(H1N1)) pdm092014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Camphor-based symmetric diimines as inhibitors of influenza virus reproduction.
AID1156042Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID778918Cytotoxicity against MDCK cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.
AID1124987Antiviral activity against rimantidine, amantadine-resistant Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of viral replication by hemagglutinin titer assay2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Camphor-based symmetric diimines as inhibitors of influenza virus reproduction.
AID1156050Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1156043Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1156044Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as 2 log10 reduction in virus yield after 24 hrs by qRT-PCR analysis2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1511218Inhibition of diphtheria induced toxicity in human A549 cells assessed as protection fold at 30 uM incubated for 20 hrs followed by replacement of [14c]-Leucine containing medium and measured after 4 hrs by liquid scintillation analysis relative to ABMA2019ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8
DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses.
AID1124986Cytotoxicity against MDCK cells assessed as cell viability after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Camphor-based symmetric diimines as inhibitors of influenza virus reproduction.
AID778917Antiviral activity against Influenza virus A/California/07/09 (H1N1)pdm09 infected in MDCK cells assessed as inhibition of viral replication incubated for 1 hr prior to viral infection measured after 48 hrs by hemagglutination reaction2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.
AID1426030Antiviral activity against Influenza A virus (A/California/07/09(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 48 hrs by hemagglutination test2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID778916Selectivity index, ratio of CTD50 for MDCK cells to EC50 for Influenza A virus California/07/09(H1N1) pdm09 infected in MDCK cells2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.
AID1156045Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTS assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1426031Selectivity index, ratio of CTD50 for MDCK cells to ED50 for Influenza A virus (A/California/07/09(H1N1))2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID1156040Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) harboring M2 S31N/V27T double mutant channel infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (15.00)29.6817
2010's11 (55.00)24.3611
2020's6 (30.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.84 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index35.06 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		3.2250adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
memantine
[no description available]		2.2110adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
nalidixic acid
[no description available]		2.08101,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
ribavirin
Rebetron: Rebetron is tradename		2.21101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
amantadine hydrochloride
[no description available]		2.4420hydrochlorideantiviral agent;
dopamine agonist;
NMDA receptor antagonist
camphora
camphora: a component of Guanxingao, a kind of traditional Chinese rubber electuary medicine which is able to either cure or guard against coronary heart disease and angina pectoris. (R)-camphor : The (R)- enantiomer of camphor.		2.830camphor
bafilomycin a1
bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.		2.2110cyclic hemiketal;
macrolide antibiotic;
oxanes		apoptosis inducer;
autophagy inhibitor;
bacterial metabolite;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
ferroptosis inhibitor;
fungicide;
potassium ionophore;
toxin
deitiforin
deitiforin: Russian drug		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Infections, Orthomyxoviridae
[description not available]		02.110
Orthomyxoviridae Infections
Virus diseases caused by the ORTHOMYXOVIRIDAE.		02.110
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510